يعرض 1 - 10 نتائج من 20 نتيجة بحث عن '"Reese, Peter P"', وقت الاستعلام: 0.79s تنقيح النتائج
  1. 1
    دورية أكاديمية

    الإتاحة: https://doi.org/10.6084/m9.figshare.25918899.v110.6084/m9.figshare.2591889910.1097/ju.000000000000233110.1038/ki.2015.32110.1002/jbmr.255310.2215/cjn.0434051410.1007/s00198-014-2998-510.1016/s0272-6386Test(98)70136-210.1093/ndt/16.11.223210.1016/j.juro.2013.09.02110.1016/j.juro.2016.07.09010.1038/ki.1979.17310.1111/j.1464-410x.1984.tb05346.x10.1681/asn.201812124110.1016/s0022-5347(01)66321-310.1080/10503307.2014.89777010.1177/014572170730841210.1001/jamainternmed.2013.215210.1016/s0002-8223(02)90347-010.2105/ajph.91.10.168610.1093/her/14.3.399
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Using_structured_problem_solving_to_promote_fluid_consumption_in_the_prevention_of_urinary_stones_with_hydration_PUSH_trial/25918899/1Test

  2. 2
    دورية أكاديمية

    الإتاحة: https://doi.org/10.6084/m9.figshare.2591889910.1097/ju.000000000000233110.1038/ki.2015.32110.1002/jbmr.255310.2215/cjn.0434051410.1007/s00198-014-2998-510.1016/s0272-6386Test(98)70136-210.1093/ndt/16.11.223210.1016/j.juro.2013.09.02110.1016/j.juro.2016.07.09010.1038/ki.1979.17310.1111/j.1464-410x.1984.tb05346.x10.1681/asn.201812124110.1016/s0022-5347(01)66321-310.1080/10503307.2014.89777010.1177/014572170730841210.1001/jamainternmed.2013.215210.1016/s0002-8223(02)90347-010.2105/ajph.91.10.168610.1093/her/14.3.39910.1016/j.crohns.2011.06.001
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Using_structured_problem_solving_to_promote_fluid_consumption_in_the_prevention_of_urinary_stones_with_hydration_PUSH_trial/25918899Test

  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Kim, Myung-Ho; Sise, Meghan E.; Xu, Min; Goldberg, David S.; Fontana, Robert J.; Kort, Jens J.; Alloway, Rita R.; Durand, Christine M.; Brown, Robert S.; Levitsky, Josh; Gustafson, Jenna L.; Reese, Peter P.; Chung, Raymond T. (2023). "Early initiation of glecaprevir/pibrentasvir after transplantation of HCV- viremic kidneys into HCV- negative recipients is associated with normalization in the altered inflammatory milieu." Clinical Transplantation 37(4): n/a-n/a.; https://hdl.handle.net/2027.42/176299Test; Clinical Transplantation; Schachtner T, Stein M, Babel N, Reinke P. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015; 15 ( 8 ): 2159 - 2169.; US Department of Health and Human Services. Health Resources and Services Administration (HRSA) organ procurement transplant network. National data. Accessed August 22, 2022. https://optn.transplant.hrsa.gov/dataTest/; Roth D, Ladino M. Transplantation of kidneys from HCV-positive donors: how to best use a scarce resource. J Am Soc Nephrol. 2017; 28 ( 11 ): 3139 - 3141.; Schaubel DE, Tran AH, Abt PL, Potluri VS, Goldberg DS, Reese PP. Five-year allograft survival for recipients of kidney transplants from hepatitis C virus infected vs uninfected deceased donors in the direct-acting antiviral therapy era. JAMA. 2022; 328 ( 11 ): 1102 - 1104.; Khera T, Du Y, Todt D, et al. Long-lasting imprint in the soluble inflammatory milieu despite early treatment of acute symptomatic hepatitis C. J Infect Dis. 2021; 226: 441 - 452.; Hengst J, Falk CS, Schlaphoff V, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis. 2016; 214 ( 12 ): 1965 - 1974.; Seifert ME, Agarwal G, Bernard M, et al. Impact of subclinical borderline inflammation on kidney transplant outcomes. Transplant Direct. 2021; 7 ( 2 ): e663.; Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev. 2017; 30 ( 2 ): 503 - 528.; Molnar MZ, Potluri VS, Schaubel DE, et al. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant. 2022; 22 ( 2 ): 599 - 609.; Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019; 19 ( 11 ): 3046 - 3057.; Sise ME, Goldberg DS, Kort JJ, et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): an open-label study of combined Glecaprevir and Pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020; 31 ( 11 ): 2678 - 2687.; Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma. Immune Netw. 2018; 18 ( 5 ): e33.; Aarreberg LD, Wilkins C, Ramos HJ, et al. Interleukin-1β signaling in dendritic cells induces antiviral interferon responses. mBio. 2018; 9 ( 2 ): e00342 - 18.; Orzalli MH, Smith A, Jurado KA, Iwasaki A, Garlick JA, Kagan JC. An antiviral branch of the IL-1 signaling pathway restricts immune-evasive virus replication. Mol Cell. 2018; 71 ( 5 ): 825 - 840.; Lee A, Park SP, Park CH, et al. IL-4 induced innate CD8+ T cells control persistent viral infection. PLoS Pathog. 2015; 11 ( 10 ): e1005193.; Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Interleukin-17—a multifaceted cytokine in viral infections. J Cell Physiol. 2021; 236 ( 12 ): 8000 - 8019.; Abend JR, Low JA, Imperiale MJ. Inhibitory effect of gamma interferon on BK virus gene expression and replication. J Virol. 2007; 81 ( 1 ): 272 - 279.; Sadeghi M, Daniel V, Schnitzler P, et al. Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation. 2009; 88 ( 9 ): 1109 - 1116.; Perez S, Kaspi A, Domovitz T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019; 15 ( 6 ): e1008181.; Hlady RA, Zhao X, El Khoury LY, et al. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology. 2022; 75 ( 4 ): 983 - 996.; Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated view on kidney transplant from HCV-infected donors and DAAs. Pharmaceutics. 2021; 13 ( 4 ): 496.; Mota AP, Vilaça SS. Cytokines signatures in short and long-term stable renal transplanted patients. Cytokine. 2013; 62 ( 2 ): 302 - 309.; Ito A, Sugimura J, Matsuura T, Abe T, Obara W. Plasma cytokine levels before and 1 year after successful living-donor renal transplantation. Renal Replace Ther. 2020; 6 ( 1 ): 48.

  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية